Premium
Retroperitoneal lymph node dissection in patients with interaortocaval lymph node metastases of transitional cell carcinoma of the urinary tract
Author(s) -
KIM CHUL JANG,
WAKABAYASHI YOSHIHIKO,
KUSHIMA RYOJI,
SAKANO YUJI,
YOSHIKI TATSUHIRO,
OKADA YUSAKU
Publication year - 2004
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2003.00776.x
Subject(s) - medicine , lymph node , retroperitoneal lymph node dissection , chemotherapy , cisplatin , dissection (medical) , lymph , metastasis , transitional cell carcinoma , surgery , urinary system , urology , cancer , radiology , bladder cancer , testicular cancer , pathology
Three patients suffered from renal pelvic, ureteral and bladder cancers that were treated with both standard surgical treatments and two adjuvant cycles of cisplatin‐based combination chemotherapy. Metastases of interaortocaval lymph nodes were detected in all patients between 9 and 33 months from the surgery for primary lesions. All patients received three cycles of cisplatin‐based combination chemotherapy and retroperitoneal lymph node dissection (RPLND). The chemotherapy achieved partial response (62–98%). Two patients with viable cancer cells died with hepatic metastases; the first 15 months and the second 25 months from the date of diagnosis of distant lymph node metastasis. The third patient, who had no viable cancer cells, remains alive and disease‐free 36 months later. Therefore, RPLND after chemotherapy provides prognostic information that helps to define patients who might benefit from additional systemic chemotherapy.